Restoring MHC class I antigen presentation to enhance anti-tumour immunity

This project will use whole genome CRISPR-Cas9 screening together with biochemical, cell and molecular biology and bioinformatics techniques and in vivo tumour models to identify strategies to restore cell surface MHC-I antigen presentation in MHC-I low tumours that fail to respond to ICIs. The goal of this work is to promote effective tumour-specific T cell responses by reinstating surface MHC I expression in cancer cells as a means to overcome resistance to ICI therapy.